Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (200)	8/15/2000 11:16:04 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Our plan of operations for the next 12 months includes the following elements: o Continue to conduct internal research and development with respect to our core technologies and other product candidates that we may identify o Conduct Phase I clinical studies of Triapine in the United States for safety and dosage o File investigational new drug application(s) with the FDA for "armed" TAPET vectors and conduct Phase I clinical studies in the United States and Europe for the safety and selective tumor accumulation of several "armed" and "unarmed" bacterial constructs using our TAPET delivery system o Continue to support research and development being performed at Yale University and by other collaborators o Continue to seek collaborative partnerships, joint ventures, co-promotional agreements or other arrangements with third parties o Conduct preclinical toxicology studies on a Sulfonyl Hydrazine agent and evaluate its suitability to proceed to clinical trials We currently estimate that our existing cash, cash equivalents and long term investments of $27,216,533 will be sufficient to fund our planned operations through 2001. As of June 30, 2000 we estimate that the amount required to fund all operations for the next twelve months is approximately $15.0 million. However, our cash requirements may vary materially from those now planned because of the results of research and development, clinical trials, results of product testing, relationships with strategic partners, changes in focus and direction of our research and development programs, competitive and technological advances, the regulatory process in the United States and abroad and other factors From latest 10Q Jim